Cerc

The power ministry has asked Central Electricity Regulatory Authority (CERC) to initiate the process of coupling multiple power exchanges, a mechanism which seeks to ensure uniformity in price discovery of energy at trading platforms. At present India has three power exchanges — Indian Electricity Exchange (IEX), Power Exchange of India (PXIL) and Hindustan Power Exchange (HPX). In the present scenario, buyers and sellers at each exchange do trading of electricity and discover spot price separately at these exchanges. After coupling of exchanges, the price discovery would be uniform. In a communique to the power regulator CERC, the ministry said, “Several stakeholders approached the Ministry of Power on the subject of market coupling in the context of multiple power exchanges.” “The ministry of power has decided to go ahead with the process...CERC is requested to take suitable action, so that the process of consultation and the finalisation of the construct for its implementation is done expeditiously and the same can be implemented.” Naveen Singh, head, business development at Hindustan Power Exchange, said in a statement that the decision to implement market coupling on power exchanges is a welcome move for the power market. “We thank the power minister and the power ministry for initiating such a transformative reform. We are confident that the CERC would soon come up with the necessary regulatory framework to ensure its implementation at the earliest.” He pointed out t...

• COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared to placebo (n=62, odds ratio [OR] = 2.62, p=0.059) • A prespecified subgroup analysis of patients 60 years of age showed that CERC-002 treatment led to a greater than 3-fold increase in likelihood of avoiding respiratory failure and death compared to placebo (n=33, OR = 3.38, p=0.054) • 28-day mortality was reduced by approximately 50% in patients treated with CERC-002 (3 patients) vs. placebo (6 patients). There were a total of 4 COVID-19 related deaths in patients on CERC-002 vs. 9 on placebo as of December 2020. These data will be updated and analyzed at the 60-day timepoint • Importantly, CERC-002 showed activity on top of corticosteroids in COVID-19 ARDS (>90% of patients in the trial received corticosteroids and >60% received remdesivir) • CERC-002 dramatically and rapidly reduced serum free-LIGHT levels • CERC-002 was well tolerated with no drug related SAEs and no clinically meaningful differences in immunosuppression or other SAEs between CERC-002 and placebo • The company intends to meet with the FDA and believes that these data support the initiation of a registration trial and filing for Breakthrough Therapy Designation. Additionally, the company is continuing its program in severe pediatric-onset Crohn’s dise...

• Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments • Mean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002 • Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score) • CERC-002 was well tolerated with no drug-related severe adverse events • Cohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21 • Promising initial results support expansion to patients with moderate to severe ulcerative colitis refractory to anti-TNF alpha therapies • The Company believes this second positive proof-of-concept study with CERC-002 further validates the LIGHT mechanism of action in inflammatory diseases ROCKVILLE, Md. and CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (TNFSF14)) monoclonal antibody, in adult patients with mod...

What are Same-Day CEREC Crowns? A crown is a type of Traditional dental crowns require two dentist visits. At the first appointment, the dentist prepares your tooth by removing any decay and damaged tooth structure and shapes the tooth for the crown. The dentist then takes an impression of the prepared tooth and sends it to the dental laboratory that will make your crown. You'll have to wear a temporary crown until your second appointment several weeks later. Then, once the lab has finished making the permanent crown, you'll return to have it fitted and cemented in place. Same-day CEREC crowns are different. CEREC is short for Chairside Economical Restoration of Esthetic Ceramics. The name refers to the fact that the crown is made chairside in your dentist's office, without the need for a dental lab. CEREC uses revolutionary computer-aided design and manufacturing (CAD/CAM) technology. It allows your dentist to design, fabricate, and place your single visit. The entire process takes just a few hours. There's no need for additional appointments or temporary crowns in most cases. 1 Who is a Candidate for CEREC Crowns? Most people who need a crown are candidates for a same-day CEREC restoration. The procedure is ideal if you have a tooth that's damaged, decayed, worn down, or misshapen. Dentists also place crowns on teeth with root canals to protect them from breaking. For minor tooth decay, support the tooth and prevent future problems from developing. 2 CEREC Crowns Procedu...

Our Expertise ​ For more than half a century, CERC has provided compassionate, respectful care to infants, children and adults with developmental disabilities, such as intellectual disabilities, autism, language disorders, learning disabilities, cerebral palsy, other neuromuscular disorders and behavioral problems. Our family-centered approach to care helps make our multidisciplinary teams of specialists even more effective, as they conduct about 55,000 visits with some 7,500 individuals and their families every year. Get to know our Look at Find the Contact information - CERC Children's Evaluation & Rehabilitation Center The Van Etten Building 1225 Morris Park Avenue Bronx, NY 10461 Call 718-430-8500 to schedule an appointment.